Company profile
ABEONA THERAPEUTICS INC.
NASDAQ:ABEOBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEXIGANAN ACETATE | phase3 | — | 2 | no active trials |
| Prademagene Zamikeracel | approved | — | 1 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05725018 | phase3 | active_not_recruiting | 2023-04-02 | 2025-09-30 | Abeona Therapeutics, Inc | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients |
| NCT00385502 | phase2 | completed | 2006-09-01 | 2008-06-01 | Abeona Therapeutics, Inc | A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail |
| NCT03315182 | phase1_2 | terminated | 2017-10-16 | 2022-04-07 | Abeona Therapeutics, Inc | Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB |
| NCT01263379 | phase1_2 | completed | 2010-10-05 | 2022-03-09 | Abeona Therapeutics, Inc | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa |
| NCT00563433 | phase3 | completed | 1994-08-01 | 1996-07-01 | Abeona Therapeutics, Inc | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125807 | BLA | Abeona Therapeutics Inc. | ||||
Loading… | ||||||